Every Dose Built from Scratch

Ex vivo gene therapies that modify a patient's own cells require manufacturing each dose as a unique, patient-specific product — a "batch of one" that fundamentally prevents economies of scale. Bluebird bio, the pioneer of lentiviral gene therapy, achieved three FDA approvals (Zynteglo for beta-thalassemia, Lyfgenia for sickle cell disease, Skysona for cerebral adrenoleukodystrophy) but accumulated $4.3 billion in losses and was acquired for less than $30M in 2025 because it could not manufacture fast enough or cheaply enough to sustain operations. Manufacturing timelines vary 70–105 days per patient, and only 11 patients started Zynteglo treatment in Q1 2025 — far below the 40 quarterly starts needed for breakeven. Across the broader gene therapy field, 74% of FDA Complete Response Letters from 2020–2024 were driven by manufacturing and quality deficiencies.

Gene therapy offers curative treatment for thousands of genetic diseases affecting millions of patients globally. But the autologous manufacturing model (extract patient cells → modify with viral vectors → quality-test → reinfuse) means each dose is a custom biomanufacturing run. At current costs ($2.8M list price for Zynteglo, $3.1M for Lyfgenia), only ultra-rare diseases with tiny patient populations can sustain this model — and even then, no autologous gene therapy company has achieved profitability. Extending gene therapy to more common conditions (sickle cell disease affects ~100,000 people in the US alone) requires a manufacturing paradigm that does not exist.

Bluebird bio's lentiviral vector approach faced variable transduction efficiency (the percentage of patient cells successfully modified varies per batch), requiring extensive per-batch quality testing and leading to unpredictable timelines. The company attempted manufacturing partnerships with contract development and manufacturing organizations (CDMOs), but revealed $100–200M in accounting errors from mischaracterized CDMO lease liabilities. Lentiviral vectors also raised safety concerns — FDA restricted Skysona after blood cancer reports in treated patients, demonstrating insertional mutagenesis risk inherent to integrating vectors. The broader AAV gene therapy industry faces a parallel crisis: only 20–30% of AAV capsids contain the therapeutic gene (the rest are empty), batch-to-batch variability is high, yields are limited (~10^14 viral genomes per liter, sufficient for ~2 patients per 200L batch), and Sarepta's AAV-based Elevidys was linked to three patient deaths from acute liver failure.

In vivo gene therapy (delivering vectors directly to patients rather than modifying their cells ex vivo) could eliminate the batch-of-one constraint by enabling standardized, shelf-stable products. Non-viral delivery systems (lipid nanoparticles, polymer nanoparticles) that avoid viral vector manufacturing entirely are advancing but have not yet achieved the tissue-targeting specificity of viral vectors for genetic diseases. For AAV-based therapies, solving the empty capsid problem (separating full from empty capsids at scale) and increasing per-batch yields by 10–100× would enable treatment of larger patient populations. Base editing and prime editing technologies that make precise genetic changes without requiring viral vector integration could reduce safety risks.

A team could develop a manufacturing process simulation model for autologous gene therapy, identifying which steps contribute most to cost and variability and testing scenarios for automation and standardization. A more research-oriented team could compare delivery efficiency of non-viral nanoparticle systems versus AAV vectors in a cell culture model, quantifying the transduction efficiency gap that must be closed. Relevant disciplines: bioengineering, biomedical engineering, health economics, manufacturing systems engineering.